Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies
書誌事項
- 公開日
- 2018-10-12
- 資源種別
- journal article
- 権利情報
-
- https://creativecommons.org/licenses/by/4.0
- https://creativecommons.org/licenses/by/4.0
- DOI
-
- 10.1038/s41380-018-0252-9
- 公開者
- Springer Science and Business Media LLC
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>Alterations in glutamatergic neurotransmission are implicated in the pathophysiology of depression, and the glutamatergic system represents a treatment target for depression. To summarize the nature of glutamatergic alterations in patients with depression, we conducted a meta-analysis of proton magnetic resonance (<jats:sup>1</jats:sup>H-MRS) spectroscopy studies examining levels of glutamate. We used the search terms: <jats:italic>depress* AND</jats:italic> (<jats:italic>MRS OR</jats:italic> “<jats:italic>magnetic resonance spectroscopy</jats:italic>”). The search was performed with MEDLINE, Embase, and PsycINFO. The inclusion criteria were <jats:sup>1</jats:sup>H-MRS studies comparing levels of glutamate + glutamine (Glx), glutamate, or glutamine between patients with depression and healthy controls. Standardized mean differences (SMD) were calculated to assess group differences in the levels of glutamatergic neurometabolites. Forty-nine studies met the eligibility criteria, which included 1180 patients and 1066 healthy controls. There were significant decreases in Glx within the medial frontal cortex (SMD = −0.38; 95% CI, −0.69 to −0.07) in patients with depression compared with controls. Subanalyses revealed that there was a significant decrease in Glx in the medial frontal cortex in medicated patients with depression (SMD = −0.50; 95% CI, −0.80 to −0.20), but not in unmedicated patients (SMD = −0.27; 95% CI, −0.76 to 0.21) compared with controls. Overall, decreased levels of glutamatergic metabolites in the medial frontal cortex are linked with the pathophysiology of depression. These findings are in line with the hypothesis that depression may be associated with abnormal glutamatergic neurotransmission.</jats:p>
収録刊行物
-
- Molecular Psychiatry
-
Molecular Psychiatry 24 (7), 952-964, 2018-10-12
Springer Science and Business Media LLC
